ArticleMolecular therapy : the journal of the American Society of Gene Therapy2019
Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Rare protein-coding variation and the genetic architecture of height in >1.4 million individuals.medRxiv : the preprint server for health sciences · 2026Article
- Current status of nano-embedded growth factors and stem cells delivery to bone for targeted repair and regeneration.Journal of orthopaedic translation · 2025Review
- Inadequate linear catch-up growth in children born small for gestational age: Influencing factors and underlying mechanisms.Reviews in endocrine & metabolic disorders · 2024Review
- Gut microbiota in regulation of childhood bone growth.Experimental physiology · 2024Review
- Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity.Frontiers in endocrinology · 2024Article
- Promoting Articular Cartilage Regeneration through Microenvironmental Regulation.Journal of immunology research · 2024Review
- Recent development in multizonal scaffolds for osteochondral regeneration.Bioactive materials · 2023Review
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.Acta biochimica et biophysica Sinica · 2023Review
- Article
- Optimizing Delivery of Therapeutic Growth Factors for Bone and Cartilage Regeneration.Gels (Basel, Switzerland) · 2023Review
- Nutrient-regulated dynamics of chondroprogenitors in the postnatal murine growth plate.Bone research · 2023Article
- Long-acting growth hormone in 2022.Pediatric investigation · 2023Review
- Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology.Frontiers in endocrinology · 2023Review
- Injectable hydrogel loaded with bilayer microspheres to inhibit angiogenesis and promote cartilage regeneration for repairing growth plate injury.Frontiers in bioengineering and biotechnology · 2023Article
- Long acting growth hormone (LAGH), an update.Frontiers in pediatrics · 2023Review
- Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.American journal of ophthalmology · 2022Observational
- Progress on growth promoting therapies other than growth hormone.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Insulin-like growth factor-1 in articular cartilage repair for osteoarthritis treatment.Arthritis research & therapy · 2021Review
- Physiological regulation of bone length and skeletal proportion in mammals.Experimental physiology · 2021Review
- Strategies for Articular Cartilage Repair and Regeneration.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Recombinant human growth hormone (GH) is commonly used to treat short stature in children. However, GH treatment has limited efficacy, particularly in severe, non-GH-deficient conditions such as chondrodysplasias, and potential off-target effects. Because short stature results from decreased growth plate chondrogenesis, we developed a cartilage-targeting single-chain human antibody fragment (CaAb) aiming to deliver therapeutic molecules to the growth plate, thereby increasing treatment efficacy while minimizing adverse effects on other tissues. To this end, we created fusion proteins of these CaAbs conjugated with insulin-like growth factor 1 (IGF-1), an endocrine and/or paracrine factor that positively regulates chondrogenesis. These CaAb-IGF-1 fusion proteins retained both cartilage binding and IGF-1 biological activity, and they were able to stimulate bone growth in an organ culture system. Using a GH-deficient (lit) mouse model, we found that subcutaneous injections of these CaAb-IGF-1 fusion proteins increased overall growth plate height without increasing proliferation in kidney cortical cells, suggesting on-target efficacy at the growth plate and less off-target effect on the kidney than IGF-1 alone. Alternate-day injections of these fusion proteins, unlike IGF-1 alone, were sufficient to produce a therapeutic effect. Our findings provide proof of principle that targeting therapeutics to growth plate cartilage can potentially improve treatment for childhood growth disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.